Nuvalent/$NUVL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nuvalent
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Ticker
$NUVL
Sector
Primary listing
Employees
234
Headquarters
Website
Nuvalent Metrics
BasicAdvanced
$9.7bn
-
-$6.05
1.15
-
Price and volume
Market cap
$9.7bn
Beta
1.15
52-week high
$123.62
52-week low
$71.13
Average daily volume
3.1m
Financial strength
Current ratio
16.137
Quick ratio
15.885
Profitability
Effective tax rate (TTM)
-0.13%
Management effectiveness
Return on assets (TTM)
-22.51%
Return on equity (TTM)
-41.19%
Valuation
Price to book
8.28
Price to tangible book (TTM)
8.28
Price to free cash flow (TTM)
-29.337
Free cash flow yield (TTM)
-3.41%
Free cash flow per share (TTM)
-4.201
Growth
Earnings per share change (TTM)
37.18%
3-year earnings per share growth (CAGR)
51.79%
What the Analysts think about Nuvalent
Analyst ratings (Buy, Hold, Sell) for Nuvalent stock.
Nuvalent Financial Performance
Revenues and expenses
Nuvalent Earnings Performance
Company profitability
Nuvalent News
AllArticlesVideos
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
MarketBeat·4 days ago
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
Reuters·5 days ago
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
Business Wire·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs